Cargando…
The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
SIMPLE SUMMARY: Due to the lack of selectivity and the severe side-effects, cytostatics are the drugs of the present but not of the future and consequently new anticancer strategies must be developed. After binding to the neurokinin-1 receptor (NK-1R), NK-1R antagonists exert antitumor actions (anti...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564414/ https://www.ncbi.nlm.nih.gov/pubmed/32962202 http://dx.doi.org/10.3390/cancers12092682 |